home > ict > autumn 2019 > the burden of time
International Clinical Trials

The Burden of Time

“Burdens are for shoulders strong enough to carry them” Margaret Mitchell

There is a general consensus of the need to increase the opportunities for patients and their family members to take part in appropriate research. This is because the range of patient groups and supporter experiences are pivotal to the success of studies and the confident extrapolation of data. Similarly, improving participant retention is also a key concern, and there is a drive to ensure, rightly, that patients are not excluded or unnecessarily discouraged from taking part.

There has been a huge shift towards patient-centred approaches in dementia research with the increased involvement of patient participation involvement groups as it is recognised that the goodwill of participant groups is enhanced by a positive research experience and hindered by a poor one. Therefore, a great deal of consideration has been given to factors that may influence participant burden.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Shani McCoy has worked in research delivery for the R&D department at Berkshire Healthcare Foundation Trust for a total of five years. Prior to this, she worked on a number of her own research studies both behavioural and neuroscience-based. Shani currently works in the trust as a Clinical Research Practitioner for the Memory and Cognition Research Unit based at the University of Reading, UK, delivering a variety of research protocols in the field of dementia and neurodegenerative disorders. She is a member of Join Dementia Lead for Berkshire, which is the national dementia research database of the NIHR.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement